Excellent point. Your logical assumption, plus AGN's history of strong 4th quarter performance -- along with positive "macro-economic" data showing better than average recovery -- I would anticipate that Allergan should report a good quarter driven by strong sales in it's Botox franchise. The "approval for migraine" will be huge. however; it will take about 4 to 6 quarters to reach it's full effect -- sort-a-like -- a rising tide effect. ***But also throw into the mix: Lap-Band expansion; and approval of other AGN's products in several global markets and you could make a case for geometric sales growth in this company's near future. What a bonanza!!!!!